<DOC>
	<DOCNO>NCT00421434</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy nitazoxanide-peginterferon nitazoxanide-peginterferon-ribavirin combination regimen compare standard care ( peginterferon-ribavirin ) treat chronic hepatitis C genotype 4 . The study also evaluate effect study treatment regimens end treatment virologic response , ALT normalization safety parameter .</brief_summary>
	<brief_title>Study Nitazoxanide , Peginterferon , Ribavirin Combination Therapies Treatment Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Age ≥18 year . Chronic hepatitis C infection ( least 6 month ) evidence positive enzyme immunoassay antiHCVantibodies positive quantitative RTPCR amplification HCV RNA . Chronic inflammation liver biopsy compatible diagnosis chronic viral hepatitis . HCV genotype 4 . Patients previously fail respond ≥12 week peginterferonribavirin combination therapy . Females either pregnant , breastfeed use birth control sexually active . Males whose female partner pregnant . Patients cause liver disease ( i.e. , autoimmune hepatitis , decompensated liver disease ) . Patients coinfected hepatitis A virus , hepatitis B virus hepatitis D virus . Patients history alcoholism alcohol consumption &gt; 40 gram per day . Patients hemoglobinopathy ( i.e. , thalassemia major , sicklecell anemia ) . Patients concomitant condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy followup could complete . History hypersensitivity intolerance excipients comprise nitazoxanide tablet , peginterferon alfa2a injectionable solution ribavirin tablet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>